---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106534"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T16:01:23.544400+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q2 loss narrows to $13.7M; China sale to AstraZeneca now ~$210M, cash runway into 2028

## Summary
- Net loss from continuing ops $13.7M ($3.38/sh) vs $47.1M loss ($11.79/sh) in Q2 2024; revenue $1.3M.
- Sale of FibroGen China to AstraZeneca now ~$210M total consideration (up $50M), including ~$125M net cash; close expected Q3 2025.
- Cash runway extended into 2028 upon China sale close; Q2 consolidated cash $142.1M.
- Agreed with FDA on pivotal Phase 3 design for roxadustat in LR-MDS with high transfusion burden; protocol filing Q4 2025.
- Phase 2 monotherapy trial of FG-3246 in mCRPC expected to start Q3 2025; combo data from UCSF study expected Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-106534
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/0000950170-25-106534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106534
- JSON: https://secwatch.observer/filing/0000950170-25-106534.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106534.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.